PATENT CLAIM ANALYSIS

Application Number: 15995513
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-09
Patent Classification: ["424", "450000"]

Abstract:
Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.

Claim (Index 6):
The composition of  claim 5  formulated for administration by inhalation.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 94.0
- Lexical Diversity: 1.61429
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15034700', '15428461', '15106263', '14114456', '13932906']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.699019859826221
- 35 USC 102 Novelty (BERT): 0.6226667801882808
- Combined Prediction Score: 0.691384551862427
- Mean Citation Score: 253.379124
- Max Citation Score: 548.0377
- Similarity Product: 543.1487387774765

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test